NCT05567406View on ClinicalTrials.gov

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Belumosudil

Pharmaceutical form: Tablet; Route of administration: Oral

Trial Locations (3)

10595

RECRUITING

Westchester Medical Center- Site Number : 130, Valhalla

21201

RECRUITING

University of Maryland School of Medicine - Baltimore- Site Number : 128, Baltimore

33155

RECRUITING

Nicklaus Children's Hospital - Miami - Southwest 62nd Avenue- Site Number : 129, Miami

All Listed Sponsors
lead

Kadmon, a Sanofi Company

INDUSTRY

NCT05567406 - Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy | Biotech Hunter | Biotech Hunter